Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (SAVA)
NASDAQ:SAVA
SAVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $33.98
Previous CloseN/A
Volume2.36M
Average Volume (3M)758.12K
Market Cap
$109.66M
Enterprise Value-$24.94M
Total Cash (Recent Filing)$112.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 05, 2025EPS EstimateN/A
Last Dividend Ex-Date
Dec 13, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding48,307,896
10 Day Avg. Volume527,368
30 Day Avg. Volume758,120
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-20.41
Enterprise Value/Gross Profit-130.59
Enterprise Value/Ebitda0.20
Forecast
1Y Price Target
$2.00Price Target Upside-6.98% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Market DemandThere is an unmet medical need for anti-seizure treatment options, suggesting potential demand for new solutions like simufilam.
New OpportunitiesThe company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders is seen as a positive development.
Bears Say
Clinical TrialsResults from the 76-week ReFocus-ALZ Phase 3 trial with simufilam in patients with mild-to-moderate Alzheimer’s disease did not meet the study’s pre-specified endpoints.
Financial RisksInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.
Cassava Sciences News
SAVA FAQ
What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was $1.15 and its highest was $33.98 in the past 12 months.
What is Cassava Sciences’s market cap?
Cassava Sciences’s market cap is $109.66M.
When is Cassava Sciences’s upcoming earnings report date?
Cassava Sciences’s upcoming earnings report date is Nov 05, 2025 which is in 60 days.
How were Cassava Sciences’s earnings last quarter?
Cassava Sciences released its earnings results on Aug 14, 2025. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.92.
Is Cassava Sciences overvalued?
According to Wall Street analysts Cassava Sciences’s price is currently Overvalued.
Does Cassava Sciences pay dividends?
Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here
What is Cassava Sciences’s EPS estimate?
Cassava Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cassava Sciences have?
Cassava Sciences has 48,307,896 shares outstanding.
What happened to Cassava Sciences’s price movement after its last earnings report?
Cassava Sciences reported an EPS of -$0.92 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.702%.
Which hedge fund is a major shareholder of Cassava Sciences?
Currently, no hedge funds are holding shares in SAVA
Cassava Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$2.00 (-6.98% Downside)
$2.00 (-6.98% Downside)
Blogger Sentiment
Bearish
SAVA Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.10%
12-Months-Change
Fundamentals
Return on Equity
-88.95%
Trailing 12-Months
Asset Growth
-44.42%
Trailing 12-Months
Company Description
Cassava Sciences
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Technical Analysis
Ownership Overview
5.23% Insiders
7.24% Mutual Funds
2.57% Other Institutional Investors
80.31% Public Companies and Individual Investors